Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathilde Jalving

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
The Oncologist|June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsHui K Gan, Michael Millward, Mathilde Jalving, et al.
Rheumatology (Oxford, England)|February 9, 2024
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirementOlof C B Vermeulen, Elisabeth Brouwer, Riemer H J A Slart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 ProbodyLaura Kist de Ruijter, Jahlisa S Hooiveld-Noeken, Danique Giesen, et al.
Cell Death & Disease|June 28, 2022
Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiationChristos E Zois, Anne M Hendriks, Syed Haider, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Heliyon|January 8, 2024
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocolPhyllis van der Ploeg, Cynthia Se Hendrikse, Anna Mj Thijs, et al.
International Journal of Cancer|August 22, 2024
B cells critical for outcome in high grade serous ovarian carcinomaAnnegé Vledder, Sterre T Paijens, Dominik Loiero, et al.
The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.
Familial Cancer|May 5, 2025
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical dataLieke Lanjouw, Claire J H Kramer, Arja Ter Elst, et al.
Nature Communications|September 3, 2024
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I studyAnneke L Eerkens, Koen Brummel, Annegé Vledder, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
The Oncologist|June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsHui K Gan, Michael Millward, Mathilde Jalving, et al.
Rheumatology (Oxford, England)|February 9, 2024
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirementOlof C B Vermeulen, Elisabeth Brouwer, Riemer H J A Slart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 ProbodyLaura Kist de Ruijter, Jahlisa S Hooiveld-Noeken, Danique Giesen, et al.
Cell Death & Disease|June 28, 2022
Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiationChristos E Zois, Anne M Hendriks, Syed Haider, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Heliyon|January 8, 2024
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocolPhyllis van der Ploeg, Cynthia Se Hendrikse, Anna Mj Thijs, et al.
International Journal of Cancer|August 22, 2024
B cells critical for outcome in high grade serous ovarian carcinomaAnnegé Vledder, Sterre T Paijens, Dominik Loiero, et al.
The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.
Familial Cancer|May 5, 2025
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical dataLieke Lanjouw, Claire J H Kramer, Arja Ter Elst, et al.
Nature Communications|September 3, 2024
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I studyAnneke L Eerkens, Koen Brummel, Annegé Vledder, et al.
Pageof 8